Pages that link to "Q48785714"

The following pages link to The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens (Q48785714):

Displaying 19 items.

• Treating Negative Symptoms in Schizophrenia: an Update (Q26744805) (← links)
• Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. (Q30366697) (← links)
• The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment (Q33920257) (← links)
• Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia (Q34481351) (← links)
• Targeting glutamate homeostasis for potential treatment of nicotine dependence (Q34502468) (← links)
• α7 Nicotinic acetylcholine receptor-specific antibody induces inflammation and amyloid β42 accumulation in the mouse brain to impair memory (Q35225004) (← links)
• Modulation of aggressive behavior in mice by nicotinic receptor subtypes (Q36144924) (← links)
• Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication (Q38286246) (← links)
• Translational psychiatry--light at the end of the tunnel. (Q38370696) (← links)
• Cognitive impairment in schizophrenia: the great unmet need (Q38673548) (← links)
• Managing Negative Symptoms of Schizophrenia: How Far Have We Come? (Q39233330) (← links)
• Alpha7 Nicotinic Acetylcholine Receptors Play a Predominant Role in the Cholinergic Potentiation of N-Methyl-D-Aspartate Evoked Firing Responses of Hippocampal CA1 Pyramidal Cells (Q41455560) (← links)
• Alpha-7 nicotinic agonist improves cognition in schizophrenia. (Q45987930) (← links)
• The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials (Q47127039) (← links)
• Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. (Q47147322) (← links)
• Complex Control of Striatal Neurotransmission by Nicotinic Acetylcholine Receptors via Excitatory Inputs onto Medium Spiny Neurons (Q62887568) (← links)
• Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence (Q89136909) (← links)
• Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients (Q89518820) (← links)
• Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats (Q90395463) (← links)